Osimertinib also improves overall survival in EGFR-mutated NSCLC

被引：0

作者：

Lichert, Frank

机构：

来源：

PNEUMOLOGIE | 2024年 / 78卷 / 03期

关键词：

D O I：

10.1055/a-2196-8365

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Innerhalb der Studie ADAURA hatte eine adjuvante Osimertinib-Therapie bei Patienten mit nicht kleinzelligem Lungenkarzinom (NSCLC) der Stadien IB-IIIA und EGFR-Mutation gegenuber Placebo ein signifikant langeres krankheitsfreies uberleben zu Folge. Nun wurden die Ergebnisse einer finalen Analyse zum Gesamtuberleben vorgestellt.

引用

页码：143 / 143

页数：1

共 50 条

[41] Continuing osimertinib in combination with chemotherapy after osimertinib failure reduces CNS progression in patients with EGFR-mutated NSCLC and CNS metastases
Li, M.
Mok, K.
Chan, L. L.
Lee, K. W. C.
Loong, H. H. F.
Lam, K. C.
Mok, F.
Lau, Y. M.
Chen, O.
Ng, J.
Lam, B.
Chen, A.
Wong, W.
Mok, T. S. K.
ANNALS OF ONCOLOGY, 2023, 34
[42] Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC
Gulikers, Judith L.
Veerman, G. D. Marijn
Jebbink, Merel
Kruithof, Paul D.
Steendam, Christi M. J.
Boosman, Rene J.
Mathijssen, Ron H. J.
Tjan-Heijnen, Vivianne C. G.
Driessen, Johanna H. M.
Dursun, Safiye
Smit, Egbert F.
Dingemans, Anne -Marie C.
van Geel, Robin M. J. M.
Croes, Sander
Hendriks, Lizza E. L.
JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (04):
[43] Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
Leonetti, A.
Verze, M.
Minari, R.
Perrone, F.
Gnetti, L.
Bordi, P.
Pluchino, M.
Nizzoli, R.
Azzoni, C.
Bottarelli, L.
Lagrasta, C. A. M.
Mazzaschi, G.
Buti, S.
Gasparro, D.
Cosenza, A.
Ferri, L.
Majori, M.
De Filippo, M.
Ampollini, L.
La Monica, S.
Alfieri, R.
Silini, E. M.
Tiseo, M.
BRITISH JOURNAL OF CANCER, 2024, 130 (01) : 135 - 142
[44] Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Wu, Yi-Long
John, Thomas
Grohe, Christian
Majem, Margarita
Goldman, Jonathan W.
Kim, Sang-We
Kato, Terufumi
Laktionov, Konstantin
Vu, Huu Vinh
Wang, Zhijie
Lu, Shun
Lee, Kye Young
Akewanlop, Charuwan
Yu, Chong-Jen
de Marinis, Filippo
Bonanno, Laura
Domine, Manuel
Shepherd, Frances A.
Zeng, Lingmin
Atasoy, Ajlan
Herbst, Roy S.
Tsuboi, Masahiro
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (03) : 423 - 433
[45] Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies
A. Leonetti
M. Verzè
R. Minari
F. Perrone
L. Gnetti
P. Bordi
M. Pluchino
R. Nizzoli
C. Azzoni
L. Bottarelli
C. A. M. Lagrasta
G. Mazzaschi
S. Buti
D. Gasparro
A. Cosenza
L. Ferri
M. Majori
M. De Filippo
L. Ampollini
S. La Monica
R. Alfieri
E. M. Silini
M. Tiseo
British Journal of Cancer, 2024, 130 : 135 - 142
[46] Overall survival with osimertinib in untreated NSCLC
Gourd, Elizabeth
LANCET ONCOLOGY, 2020, 21 (01): : E15 - E15
[47] Osimertinib for Leptomeningeal Disease in EGFR- Mutated NSCLC
Hegde, Aparna
Velcheti, Vamsidhar
JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (11) : 1705 - 1708
[48] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
Gassa, Asmae
Ozkan, Filiz
Alakus, Hakan
Bruns, Christiane
ONKOLOGE, 2021, 27 (02): : 172 - 173
[49] Liquid and Solid Rebiopsies in EGFR-Mutated NSCLC Patients
Nunes, D.
Dansin, E.
Lamblin, C.
Wasielewski, E.
Descarpentries, C.
Gregoire, V.
Copin, M. C.
Escande, F.
Cortot, A.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2237 - S2238
[50] Is Relapse-Free Survival at 2-Years an Appropriate Surrogate for Overall Survival at 5-Years in EGFR-mutated Resected NSCLC?
Garcia, M.
Schmid, S.
Hueniken, K.
Zhan, L.
Balaratnam, K.
Khan, K.
Fares, A.
Chan, S.
Smith, E.
Aggarwal, R.
Brown, M. C.
Patel, D.
Sacher, A.
Bradbury, P.
Shepherd, F. A.
Leighl, N.
Liu, G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1107 - S1108

← 1 2 3 4 5 →